Funding

Lucis Raises $8.5M Seed Round To Expand Preventive Healthcare Across Europe

Dec 16, 2025 | By Kailee Rainse

Lucis, a French startup focused on expanding access to preventive health testing, has raised $8.5 million in a seed round led by General Catalyst, with participation from Y Combinator, Kima Ventures, Motier Ventures, Circle.Co, and North South Ventures.

SUMMARY

  • Lucis, a French startup focused on expanding access to preventive health testing, has raised $8.5 million in a seed round led by General Catalyst, with participation from Y Combinator, Kima Ventures, Motier Ventures, Circle.Co, and North South Ventures.

Founded by Maxime Berthelot, Baptiste Debever, and Max Guerois, Lucis offers a platform that translates blood test results into a set of indicators tracked every six to 12 months.

The platform provides a structured view of over 180 biomarkers, covering areas like cardiometabolic health, hormones, inflammation, liver and kidney function and selected micronutrients. The goal is to help users identify potential imbalances and early signs of chronic diseases.

Lucis positions itself as a preventive tool to aid in understanding and monitoring health, emphasizing that it does not replace medical consultations, diagnoses, or prescriptions.

Read Also - Irish HealthTech Startup Smile Genius Secures €850K To Transform Clinic-Lab Collaboration

Our mission is to empower individuals to take ownership of their health by giving them a clear view of key indicators before symptoms even appear, and providing practical guidance to improve their well-being, without replacing physicians, said Maxime Berthelot, CEO and co-founder of Lucis.

Members complete check-ups through certified medical biology laboratories across Europe. The results are reviewed by a multidisciplinary medical team, with AI used to highlight key signals and track changes over time.

Instead of receiving a static report, users access a dynamic dashboard and a prioritised action plan, organised around five key areas: nutrition, supplements, physical activity, sleep and recovery, and mental health. Lucis presents this model as an extension of broader consumer health tracking, incorporating biological markers and clinical oversight to support a more structured, public health-aligned approach.

The new funding will be used to accelerate Lucis' rollout in France, the UK, Ireland, and Portugal, as well as expand into additional markets. The company will also grow its network of partner laboratories and clinicians, while further developing its AI-enabled preventive analysis and support platform.

About Lucis

Lucis empowers individuals to live healthier, longer lives by transforming simple blood tests into actionable insights. The platform helps doctors identify risks early, organize health data, and optimize patient appointments for more productive, preventive care.

Recommended Stories for You